London Co. of Virginia Cuts Stake in Bruker Corporation $BRKR

London Co. of Virginia reduced its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,783,125 shares of the medical research company’s stock after selling 225,368 shares during the period. London Co. of Virginia’s holdings in Bruker were worth $131,114,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Orbis Allan Gray Ltd acquired a new stake in Bruker during the 2nd quarter worth approximately $192,735,000. State Street Corp increased its position in Bruker by 2.5% during the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after purchasing an additional 91,706 shares in the last quarter. AQR Capital Management LLC increased its position in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. Sculptor Capital LP increased its position in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after purchasing an additional 1,756,460 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on shares of Bruker in a research report on Monday, June 1st. They set a “peer perform” rating for the company. Barclays increased their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. TD Cowen increased their target price on shares of Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $51.31.

Bruker Stock Down 1.5%

Shares of NASDAQ:BRKR opened at $55.80 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.54. The company has a 50 day moving average of $45.39 and a two-hundred day moving average of $43.94. The company has a market capitalization of $8.49 billion, a price-to-earnings ratio of -232.50, a price-to-earnings-growth ratio of 1.81 and a beta of 1.31.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same quarter last year, the company earned $0.47 earnings per share. Bruker’s revenue for the quarter was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 27.20% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.